{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T02:36:46Z","timestamp":1793759806393,"version":"4.6.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2507802"],"award-info":[{"award-number":["2023YFC2507802"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["T-B-079"],"award-info":[{"award-number":["T-B-079"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470136"],"award-info":[{"award-number":["82470136"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82570173"],"award-info":[{"award-number":["82570173"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010041","name":"Tianjin Municipal Science and Technology Committee","doi-asserted-by":"publisher","award":["25ZXZSSS00510"],"award-info":[{"award-number":["25ZXZSSS00510"]}],"id":[{"id":"10.13039\/501100010041","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Global Medical Genetics"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.gmg.2026.100107","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T16:16:30Z","timestamp":1775060190000},"page":"100107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["No significant increase in thrombotic risk following the widespread adoption of TPO-RAs in ITP: A comparative study"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5986-5407","authenticated-orcid":false,"given":"Yun","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongfeng","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renchi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.gmg.2026.100107_bib1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13045-023-01401-z","article-title":"How we treat primary immune thrombocytopenia in adults","volume":"16","author":"Liu","year":"2023","journal-title":"J. Hematol. & Oncol."},{"key":"10.1016\/j.gmg.2026.100107_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2024.132417","article-title":"Immune thrombocytopenia increases the risk of thrombosis: A two-sample Mendelian randomization study","volume":"414","author":"Yu","year":"2024","journal-title":"Int. J. Cardiol."},{"issue":"1","key":"10.1016\/j.gmg.2026.100107_bib3","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/ajh.24234","article-title":"Is ITP a thrombophilic disorder?","volume":"91","author":"Rodeghiero","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.gmg.2026.100107_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.thromres.2024.109109","article-title":"The immune thrombocytopenia paradox: Should we be concerned about thrombosis in ITP?","volume":"241","author":"Saldanha","year":"2024","journal-title":"Thromb. Res."},{"issue":"4","key":"10.1016\/j.gmg.2026.100107_bib5","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1053\/j.seminhematol.2019.09.001","article-title":"Mechanisms and therapeutic prospects of thrombopoietin receptor agonists","volume":"56","author":"Bussel","year":"2019","journal-title":"Semin Hematol."},{"issue":"3","key":"10.1016\/j.gmg.2026.100107_bib6","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/bjh.17709","article-title":"Risk factors of hospitalisation for thrombosis in adults with primary immune thrombocytopenia, including disease-specific treatments: a French nationwide cohort study","volume":"195","author":"Lafaurie","year":"2021","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.gmg.2026.100107_bib7","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.revmed.2016.09.016","article-title":"Thrombosis during thrombopoietin receptor agonist treatment for immune thrombocytopenia. A French multicentric observational study","volume":"38","author":"Weber","year":"2017","journal-title":"Rev. Med Interne"},{"issue":"8","key":"10.1016\/j.gmg.2026.100107_bib8","first-page":"617","article-title":"Chinese guideline on the diagnosis and management of adult primary immune thrombocytopenia (version 2020)","volume":"41","author":"Liu","year":"2020","journal-title":"Chin. J. Hematol."},{"issue":"23","key":"10.1016\/j.gmg.2026.100107_bib9","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv."},{"issue":"11","key":"10.1016\/j.gmg.2026.100107_bib10","first-page":"942","article-title":"The incidence and risk factors for thrombosis in primary immune thrombocytopenia","volume":"39","author":"Huang","year":"2018","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"11","key":"10.1016\/j.gmg.2026.100107_bib11","first-page":"942","article-title":"The incidence and risk factors for thrombosis in primary immune thrombocytopenia","volume":"39","author":"Huang","year":"2018","journal-title":"Chin. J. Hematol."},{"issue":"7","key":"10.1016\/j.gmg.2026.100107_bib12","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.3324\/haematol.2009.018390","article-title":"Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database","volume":"95","author":"Sarpatwari","year":"2010","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.gmg.2026.100107_bib13","article-title":"Thrombosis in patients with immune thrombocytopenia: incidence, risk, and clinical outcomes","volume":"8","author":"Goncalves","year":"2024","journal-title":"Res Pr. Thromb. Haemost."},{"key":"10.1016\/j.gmg.2026.100107_bib14","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.2147\/IJGM.S462276","article-title":"The Incidence and Characteristics of Thrombosis in Patients with Immune thrombocytopenia: A Retrospective Cohort Study","volume":"17","author":"Zhang","year":"2024","journal-title":"Int J. Gen. Med"},{"key":"10.1016\/j.gmg.2026.100107_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.thromres.2024.109109","article-title":"The immune thrombocytopenia paradox: Should we be concerned about thrombosis in ITP?","volume":"241","author":"Saldanha","year":"2024","journal-title":"Thromb. Res"},{"issue":"5","key":"10.1016\/j.gmg.2026.100107_bib16","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/bjh.17390","article-title":"Thrombosis in immune thrombocytopenia - current status and future perspectives","volume":"194","author":"Swan","year":"2021","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.gmg.2026.100107_bib17","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/bjh.14412","article-title":"Procoagulant profile in patients with immune thrombocytopenia","volume":"175","author":"\u00c1lvarez-Rom\u00e1n","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.gmg.2026.100107_bib18","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.thromres.2023.01.012","article-title":"Platelet function and soluble P-selectin in patients with primary immune thrombocytopenia","volume":"223","author":"Mehic","year":"2023","journal-title":"Thromb. Res"},{"issue":"1","key":"10.1016\/j.gmg.2026.100107_bib19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/ajh.24234","article-title":"Is ITP a thrombophilic disorder?","volume":"91","author":"Rodeghiero","year":"2016","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.gmg.2026.100107_bib20","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00277-019-03886-6","article-title":"Evaluation of thrombotic events in patients with immune thrombocytopenia","volume":"99","author":"Ito","year":"2020","journal-title":"Ann. Hematol."},{"issue":"11","key":"10.1016\/j.gmg.2026.100107_bib21","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.3324\/haematol.2020.261099","article-title":"Splenectomy for immune thrombocytopenia: the evolution and preservation of treatment","volume":"105","author":"Remiker","year":"2020","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.gmg.2026.100107_bib22","article-title":"Severe Portal Vein Thrombosis During Eltrombopag Treatment Concomitant Splenectomy for Immune Thrombocytopenia","volume":"13","author":"Saito","year":"2021","journal-title":"Cureus"},{"issue":"23","key":"10.1016\/j.gmg.2026.100107_bib23","doi-asserted-by":"crossref","first-page":"4782","DOI":"10.1182\/blood-2012-12-467068","article-title":"Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia","volume":"121","author":"Boyle","year":"2013","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.gmg.2026.100107_bib24","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1182\/blood-2017-09-742353","article-title":"Splenectomy for immune thrombocytopenia: down but not out","volume":"131","author":"Chaturvedi","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.gmg.2026.100107_bib25","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/bjh.19077","article-title":"Is splenectomy a good strategy for refractory immune thrombocytopenia in adults?","volume":"203","author":"Godeau","year":"2023","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.gmg.2026.100107_bib26","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.revmed.2020.05.017","article-title":"Adult immune thrombocytopenia and thrombopoietin receptor agonist: Ten years later","volume":"42","author":"Ebbo","year":"2021","journal-title":"Rev. Med Interne"},{"issue":"16","key":"10.1016\/j.gmg.2026.100107_bib27","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa054626","article-title":"AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP","volume":"355","author":"Bussel","year":"2006","journal-title":"N. Engl. J. Med"},{"issue":"13","key":"10.1016\/j.gmg.2026.100107_bib28","first-page":"1171","article-title":"Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura","volume":"23","author":"Dmytrijuk","year":"2009","journal-title":"Oncol. (Williston Park"},{"issue":"9610","key":"10.1016\/j.gmg.2026.100107_bib29","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0140-6736(08)60203-2","article-title":"Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial","volume":"371","author":"Kuter","year":"2008","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.gmg.2026.100107_bib30","first-page":"2867","article-title":"Prolonged response after TPO-RA discontinuation in primary ITP: results of a prospective multicenter study","volume":"141","author":"Guillet","year":"2023","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.gmg.2026.100107_bib31","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2017-04-748707","article-title":"Safety and efficacy of long-term treatment of chronic\/persistent ITP with eltrombopag: final results of the EXTEND study","volume":"130","author":"Wong","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.gmg.2026.100107_bib32","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/ejh.12181","article-title":"Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials","volume":"91","author":"Rodeghiero","year":"2013","journal-title":"Eur. J. Haematol."},{"issue":"3","key":"10.1016\/j.gmg.2026.100107_bib33","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3892\/br.2024.1732","article-title":"Thrombopoietin receptor agonists use and risk of thrombotic events in patients with immune thrombocytopenic purpura: A systematic review and meta\u2011analysis of randomized controlled trials","volume":"20","author":"Shen","year":"2024","journal-title":"Biomed. Rep."},{"issue":"1","key":"10.1016\/j.gmg.2026.100107_bib34","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12959-023-00509-z","article-title":"Risk of thrombotic events in immune thrombocytopenia patients treated with thrombopoietic agents: a systematic review and meta-analysis","volume":"21","author":"Dong","year":"2023","journal-title":"Thromb. J."},{"key":"10.1016\/j.gmg.2026.100107_bib35","article-title":"Efficacy and safety and analysis of thrombopoietin receptor agonists for the treatment of immune thrombocytopenia in adults: analysis of a systematic review and network meta-analysis of randomized controlled trials and results of real-world safety data","volume":"12","author":"Liu","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.gmg.2026.100107_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.704093","article-title":"Comparative Efficacy and Safety of Thrombopoietin Receptor Agonists in Adults With Thrombocytopenia: A Systematic Review and Network Meta-analysis of Randomized Controlled Trial","volume":"12","author":"Deng","year":"2021","journal-title":"Front Pharm."}],"container-title":["Global Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2699940426000159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2699940426000159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T07:59:36Z","timestamp":1782201576000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2699940426000159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2699940426000159"],"URL":"https:\/\/doi.org\/10.1016\/j.gmg.2026.100107","relation":{},"ISSN":["2699-9404"],"issn-type":[{"value":"2699-9404","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"No significant increase in thrombotic risk following the widespread adoption of TPO-RAs in ITP: A comparative study","name":"articletitle","label":"Article Title"},{"value":"Global Medical Genetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gmg.2026.100107","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100107"}}